MTOR and large cell neuroendocrine carcinoma: The study showed similar genomic profiles between LCNEC and SCLC, including the high frequency of inactivating mutations in TP53 and RB1, with a significantly lower prevalence of RB1 mutations in LCNEC compared to SCLC (40%), and genetic alterations in the PI3K/AKT/mTOR pathway, which could represent potential therapeutic targets.